PaulSWisselMD
Oncology • Philadelphia, PAGastrointestinal Cancer, Hematologic Oncology
Clinical Professor--University of Pennsylvania
Dr. Wissel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3400 Civic Center Blvd
Philadelphia, PA 19104Phone+1 215-615-5858Fax+1 215-349-8144
Education & Training
Rockefeller University HospitalFellowship, Drug Metabolism and Pharmacology, 1985 - 1987
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1982 - 1985
University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1981 - 1982
Ohio State University HospitalResidency, Internal Medicine, 1979 - 1981
Columbia University Vagelos College of Physicians and SurgeonsClass of 1979
Certifications & Licensure
PA State Medical License 1989 - 2024
NC State Medical License 1992 - 2017
OH State Medical License 1980 - 1984- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Publications & Presentations
PubMed
- 20 citationsPhase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With-Mutant Metastatic Non-Small-Cell Lung Cancer.Gregory J Riely, Egbert F Smit, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam
Journal of Clinical Oncology. 2023-07-20 - 73 citationsA phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumorsA. S. T. Planting, Pieter Sonneveld, A. van der Gaast, Alex Sparreboom, M.E.L. van der Burg
Cancer Chemotherapy and Pharmacology. 2005-01-01 - 17 citationsEncorafenib plus binimetinib in patients with-mutant non-small cell lung cancer: phase II PHAROS study design.Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip, Suresh S Ramalingam, Egbert F Smit
Future Oncology. 2022-03-01
Grant Support
- Endocrinology/CancerNational Center For Research Resources1985–1986
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
